Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials.
Yutaka FujiwaraAya KuchibaTakafumi KoyamaRyunosuke MachidaAkihiko ShimomuraShigehisa KitanoToshio ShimizuNoboru YamamotoPublished in: ESMO open (2021)
Our results validate that PAMs and CTAs carry a higher infection risk in patients with advanced solid tumours compared with MTAs. We suggest that the infection risk of ICIs is a similar infection risk to MTAs.